ReCode raises another $50M; Histogen halts clinical development; 60 Degrees withdraws Covid-19 IND
ReCode Therapeutics is back with an additional $50 million more than a year after it raised $120 million.
The Menlo Park, CA-based biotech is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
